Impact Report

Overview

The report highlights a year of clinical progress, including FDA acceptance and priority review of the UX111 BLA. It reports 1,294 employees at year-end and 1,945 MWh of renewable electricity purchased through the Novato initiative. It also describes rare-disease access and community programs alongside environmental efforts such as waste diversion and My Green Lab certification.

Document

Report type: Sustainability Report
Class: Dedicated
Scope: Full report
Fiscal year: 2024
Period: 1 January 2024 – 31 December 2024
Language: English
Pages
File size

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP

Ratings

GRI level

Materiality

Assessment
Basis

Assurance

Statement included

Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services